Welcome to the LAG-3 Targeted Drug Development Summit
Harness the LAG-3 through elucidating the role of LAG-3 in immune system homeostasis, devising effective clinical strategies, and developing biomarkers to accelerate LAG-3 therapies to the clinic.
Despite the fact immune checkpoint inhibitor treatments have had revolutionary success in a variety of cancer types over the last decade, a significant number of patients do not respond, and others have severe side effects. This has resulted in a surge of investment in the field of checkpoint inhibitors.
The LAG-3 Targeted Drug Development Summit comes at a vital time for the industry, as promising clinical evidence for LAG-3 therapies continues to accumulate. There is now a competition to find the best LAG-3 application.
This meeting will provide you the opportunity to discuss the major obstacles to LAG-3 treatment development and how to get LAG-3 into clinical trials.
Attend this exclusive summit to:
Preferentially block PD-1 & LAG-3 on TILs whilst sparing Treg activation with Roche Innovation Center
Understanding how LAG-3 & PD-1 interplay with one another with Texas Tech, Incyte and Macrogenics
Gain clarity on the mechanism of action and signalling of LAG-3 with University of Pittsburgh
Enable LAG-3 success through utilizing biomarkers to maximize clinical impact with Columbia University
Hear the latest clinical data and approaches to utilizing LAG-3 beyond PD-1 cancers and speculate where the future lies with Crescendo Biologics, EpiMab and Regeneron
This is your one-of-a-kind chance to accelerate the safe development of LAG-3 treatments with maximal clinical effect in such a fast-paced business. Register your interest below to receive updates on the 2023 program.